Beta

Quoin pharmaceuticals, ltd.QNRX.US Overview

US StockHealthcare
(No presentation for QNRX)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

QNRX AI Insights

QNRX Overall Performance

QNRX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

QNRX Recent Performance

-0.18%

Quoin pharmaceuticals, ltd.

-1.10%

Avg of Sector

-0.49%

S&P500

QNRX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check QNRX's Trend

QNRX Key Information

QNRX Valuation Metrics

QNRX Profile

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Price of QNRX

QNRX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

QNRX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-26.87
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.78
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-26.87
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.78
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is QNRX's latest earnings report released?

    The most recent financial report for Quoin pharmaceuticals, ltd. (QNRX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating QNRX's short-term business performance and financial health. For the latest updates on QNRX's earnings releases, visit this page regularly.

  • How much cash does QNRX have?

    At the end of the period, Quoin pharmaceuticals, ltd. (QNRX) held Total Cash and Cash Equivalents of 3.82M, accounting for 0.19 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is QNRX's EPS continuing to grow?

    According to the past four quarterly reports, Quoin pharmaceuticals, ltd. (QNRX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -14.78K. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of QNRX?

    Quoin pharmaceuticals, ltd. (QNRX)'s Free Cash Flow (FCF) for the period is -5.04M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 125.13% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of QNRX?

    The latest valuation data shows Quoin pharmaceuticals, ltd. (QNRX) has a Price-To-Earnings (PE) ratio of -1.51 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.